Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

69.31 +1.11 (+1.63%)
Official Closing Price Updated: 7:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics
 
Via Benzinga
Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022
From Bristol Myers Squibb
Via Business Wire
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunothera 
Via Benzinga
3 Stocks Savvy Investors Are Buying Hand Over Fist
These high-flying stocks are defying the bear market. 
Via The Motley Fool
Best Stocks 2022: Why Bristol-Myers Squibb (BMY) Stock Is a Clear Winner
There's a reason BMY stock is currently winning our Best Stocks for 2022 contest. Investors should buy BMY for value, safety and dividends. 
Via InvestorPlace
Bristol Myers' Opdivo Combo Treatment Scores European Approval For Skin Cancer Setting
 
Via Benzinga
Best Stocks 2022: These 3 Factors Can Send Sonic Automotive (SAH) Stock Soaring in Q4
While Sonic Automotive isn’t in the lead for the top 10 best stocks ranking, SAH stock performs relatively well because of its fundamentals. 
Via InvestorPlace
Autolus Therapeutics Stock Jumps After Bristol Myers Pact For Safety Switch System
 
Via Benzinga
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
From Autolus Therapeutics plc
Via Globe NewsWire
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio
Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio. 
Via Talk Markets
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
 
Via Benzinga
Insiders Selling Nasdaq, Bristol-Myers Squibb And This Consumer Defensive Stock
The Nasdaq Composite dropped by around 150 points on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Bristol-Myers Squibb, Cash, Cheniere Energy And This Tech Company Are CNBC's Final Trades
On CNBC’s “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners said Bristol-Myers Squibb Co (NYSE: BMY) has a “good dividend yield” and is a &l 
Via Benzinga
Salesforce Is Among Thursday's CNBC 'Fast Money' Final Trades
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. The information is collected and refined... 
Via Benzinga
Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial
Nanobiotix (NASDAQ: NBTX) determined the recommended phase 2 dose (RP2D) of the NBTXR3 combo regime for inoperable locoregional recurrent or recurrent and metastatic head and neck squamous cell... 
Via Benzinga
3 Stocks That Could Rocket on Biden’s Cancer Moonshot
Joe Biden’s cancer moonshot gave some of the drug companies a big shot in the arm. These three stocks all are doing big things in oncology. 
Via InvestorPlace
What Are Whales Doing With Bristol-Myers Squibb
Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Amazon, Target And 3 Other Stocks Insiders Are Selling
U.S. crude oil futures traded lower this morning on Monday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
7 Penny Stocks That Actually Have a Buy Rating
Penny stocks are always a risky proposition. However, investors can still find penny stocks with buy ratings right now. 
Via InvestorPlace
US Stock Futures Down Ahead Of Fed's Rate Decision This Week, Crude Oil Drops Over 1%
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Monday after recording losses on Friday. All the three major indices recorded losses last week, with the Dow Jones dropping... 
Via Benzinga
AutoZone, bluebird bio And 3 Stocks To Watch Heading Into Monday
With US stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%
From Bristol Myers Squibb
Via Business Wire
Top US Drugmakers Exploit US Patent System To Keep Generic Competition At Bay: Report
 
Via Benzinga
Looking At Bristol-Myers Squibb's Recent Whale Trades
A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 10 strange trades. 
Via Benzinga
Bristol-Myers Squibb And 2 Other Stocks Insiders Are Selling
Gold futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Melanoma Study Achieves Key Milestone as Bristol's Flagship Treatment Secures Improvement in Survival Rates
 
Via Benzinga
Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.